Lyell Immunopharma, Inc. (LYEL)
Develops engineered T-cell therapies to fight blood cancers and solid tumors.
$12.99+0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+17.9%
The outlook
LYEL trades at $12.99, well below both its 50- and 200-day moving averages, positioning it near the lower end of its 52-week range. Analysts lean bullish with an average rating of "buy," and their price target sits roughly 194% above the current price. The overall picture is mixed—solid analyst sentiment contrasts with weak recent price momentum.
What’s behind the score
Analyst consensusBuy — 1.7 avg of 7 analysts
Price trendBelow its 50- & 200-day averages
52-week range10% of the way from its 52-week low to high
Price targetAvg target +194% vs current price
Analyst price target
~12-month · 7 analysts$38.14average target+193.6% vs now
Now $12.99
Low $12.00High $49.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$318.3M
52-wk high
$45.00
52-wk low
$9.28
50-day avg
$14.25
200-day avg
$20.72
Trailing P/E
—